Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta112
7 Related guidance
7.1 NICE has issued the following related guidance.
Cancer service guidance
-
Improving outcomes in breast cancer – manual update. NICE cancer service guidance (2002).
Clinical guidelines
-
Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. NICE clinical guideline no. 41 (2006).
-
Breast cancer (advanced). NICE clinical guideline 81 (2009).
-
Early breast cancer: diagnosis and treatment. NICE clinical guideline 80 (2009).
Technology appraisals
-
Docetaxel for the adjuvant treatment of early node-positive breast cancer. NICE technology appraisal guidance no. 109 (2006).
-
Paclitaxel for the adjuvant treatment of early node-positive breast cancer. NICE technology appraisal guidance no. 108 (2006).
-
Trastuzumab as adjuvant therapy for early stage breast cancer. NICE technology appraisal guidance no. 107 (2006).